Consumer Biotech’s Next Wave: Muscle, Sex, and Psychedelics
GLP-1 drugs have shown the world that blockbuster medicines don’t have to treat disease in...
Top 50 Investors in Biotech in 2026: Europe’s Most Active Life Sciences Funds
Who is writing the cheques that fund Europe’s next generation of medicines? Based on fund...
Billionaire wild bets on Consumer Biotech, GLP-1s, and psychedelics | Christian Angermayer | E61
Christian Angermayer became a multimillionaire before turning 25 thanks to the merger of Alnylam with...
ASCO 2026: ADC and In Vivo CAR-T Trends in Oncology
What are the biggest trends shaping oncology investment and drug development in 2026? We sat...
How Next-Generation Sequencing is Changing Biopharma Manufacturing
In the strictly regulated world of biopharmaceutical manufacturing, innovation faces a massive hurdle: the industry...
The $6 Billion Excel Illusion: Why Biotech Pipeline Forecasting is Broken (And How to Fix It)
If you sit in a Big Pharma boardroom during a pipeline review, you will inevitably...
ImCheck ex-CEO Pierre d’Epenoux talks Fundraising, France and Oncology’s Next Wave | E60
After ImCheck’s inception in 2015, Pierre took the helm through clinical development and guided the...
![CEO Jean-François Brepson on Scaling a CRO, and Selling to Charles River | E59 [Sponsored]](https://flot.bio/wp-content/uploads/2026/06/Website-Thumbnail-PathoQuest-1080x648.avif)
CEO Jean-François Brepson on Scaling a CRO, and Selling to Charles River | E59 [Sponsored]
Founded in 2010, the Institut Pasteur spinout PathoQuest sold to top CRO Charles River for...
Ex-CEO of Incyte Hervé Hoppenot on 10x Growth, Biotech Cycles, and Breaking Bureaucracy | E58
When Hervé joined Incyte in 2014, the launch of lead product Jakafi in the US...
The Biotech Equity Gap: Why Curie.Bio is Re-Writing the Founder Playbook
In the high-stakes world of drug discovery, a “brilliant idea” is often described as being...
